Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Johnson & Johnson's Current Accrued Expense for the quarter that ended in Jun. 2026 was CHF23,543 Mil.
Johnson & Johnson's quarterly Current Accrued Expense
declined
from Dec. 2025 (CHF22,088 Mil) to Mar. 2026 (CHF20,311 Mil) but then
increased
from Mar. 2026 (CHF20,311 Mil) to Jun. 2026 (CHF23,543 Mil).
Johnson & Johnson's annual Current Accrued Expense
increased
from Dec. 2023 (CHF22,669 Mil) to Dec. 2024 (CHF23,297 Mil) but then
declined
from Dec. 2024 (CHF23,297 Mil) to Dec. 2025 (CHF22,088 Mil).
Johnson & Johnson Current Accrued Expense Related Terms
Johnson & Johnson Current Accrued Expense Historical Data
* Premium members only.
The historical data trend for Johnson & Johnson's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson Current Accrued Expense Calculation
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of CHF23,543 Mil mean?
Johnson & Johnson (XSWX:JNJ) has a Current Accrued Expense of CHF23,543 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's Current Accrued Expense too high?
Johnson & Johnson's current Current Accrued Expense is CHF23,543 Mil. Overall, Johnson & Johnson has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Current Accrued Expense compare to ABBV and MRK?
Johnson & Johnson's Current Accrued Expense of CHF23,543 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current Current Accrued Expense is CHF23,543 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (XSWX:JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF155.04, compared to a current price of CHF211.35 — trading 36.3% above its estimated fair value. The current Current Accrued Expense is CHF23,543 Mil. Johnson & Johnson's overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Johnson & Johnson (XSWX:JNJ), the current Current Accrued Expense is CHF23,543 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson & Johnson (XSWX:JNJ) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued.
The current stock price of CHF211.35 is trading 36.3% above its estimated GF Value™ of CHF155.04.
GuruFocus considers Johnson & Johnson to be Significantly Overvalued.
Key valuation signals for XSWX:JNJ:
Current Accrued Expense: CHF23,543 Mil
GF Value™: CHF155.04 vs. price of CHF211.35 (36.3% above fair value)
No single metric tells the full story. See the XSWX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
24GF Score
Get the complete analysis for XSWX:JNJ
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JNJ has been successfully added to your 
